超声卵巢-附件报告和数据系统(O-RADS)与改良超声简单规则在手术证实的附件肿块评估中的比较
多中心回顾性研究纳入2008年1月至2018年12月手术病理证实的791个卵巢附件肿块,比较O-RADS 2022与改良超声简单规则(mUSR)鉴别良恶性的效能。两者敏感度与阴性预测值均高且无显著差异,但mUSR特异度和阳性预测值显著高于O-RADS,AUC为0.920对0.855(P=0.005)。
要点
- O-RADS与mUSR鉴别卵巢恶性肿瘤的敏感度均为0.96,阴性预测值均为0.99(P>0.05)。
- mUSR特异度0.88、阳性预测值0.68,均显著高于O-RADS的0.75和0.50(P<0.01)。
- CA-125仅在围绝经期/绝经后患者中改善mUSR(P=0.002)和O-RADS(P=0.005)的效能。
核心结论
- O-RADS与mUSR检测卵巢恶性肿瘤均有高敏感度和阴性预测值,但mUSR特异度和阳性预测值显著高于O-RADS;该结果支持美国放射学会(ACR)关于O-RADS 3和4类请专家超声医师会诊的建议。
研究设计与样本
- 多中心回顾性研究,纳入2008年1月至2018年12月病理证实的附件肿块患者765例共791个卵巢肿块(26个双侧),平均年龄44±15岁。
关键影像表现/征象
- 791个肿块中良性628个、交界性49个、恶性114个。
- O-RADS 2、3、4、5类的恶性率分别为0.3%、3.0%、24.9%、82.4%。
- 所有读者间对mUSR良恶性分类及O-RADS 2/3类与4/5类分类的一致性均优(kappa>0.86)。
诊断标准与关键数值
- O-RADS与mUSR敏感度和阴性预测值比较P>0.05,特异度和阳性预测值比较P<0.01,AUC比较P=0.005。
- CA-125改善mUSR效能P=0.002、改善O-RADS效能P=0.005,仅见于围绝经期/绝经后患者。
临床应用与阅片要点
- O-RADS 3和4类可参考美国放射学会(ACR)建议请专家超声医师会诊。
- mUSR为将附件肿块二分类为良性/可疑恶性的简化版IOTA简单规则。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: The aim of this study was validating Ovarian-Adnexal Reporting and Data System (O-RADS) 2022 risk estimates in surgically treated ovarian/adnexal masses comparing accuracy of O-RADS with modified ultrasound simple rules (mUSR) differentiating malignant from benign lesions. The mUSR was a simplified version of the International Ovarian Tumor Analysis (IOTA) using a binary classification of adnexal masses into benign/suspicious for malignancy.
MATERIALS AND METHODS: multisite retrospective study was conducted including patients with pathology-proven adnexal masses between January 2008 and December 2018. All ultrasound (US) video clips reviewed by an experienced radiologist with randomly selected subset were reviewed by two additional radiologists. Areas under receiver operator characteristic curves (AUCs) were compared without and with CA-125.
RESULTS: 791 ovarian masses in 765 patients (26 bilateral) (mean age: 44 ± 15 years) (628 benign, 49 borderline, and 114 malignancies) demonstrated malignancy rates of 0.3%, 3.0%, 24.9%, and 82.4% for O-RADS 2, 3, 4, and 5, respectively. O-RADS and mUSR had a sensitivity of 0.96 (confidence interval [CI]: 0.92-0.99) and 0.96 (CI: 0.91-0.98), negative predictive values (NPVs) of 0.99 (CI: 0.97-1.00) and 0.99 (CI: 0.98-1.00) (P>0.05), specificities 0.75 [CI: 0.71-0.78] and 0.88 [CI: 0.85-0.91], and positive predictive values (PPVs) 0.50 (CI: 0.44-0.55) and 0.68 (CI: 0.61-0.74) (P<0.01), respectively. The AUC was 0.855 for O-RADS and 0.920 for mUSR (P=0.005). Interobserver agreement was excellent across all readers for mUSR benign versus mUSR malignant and O-RADS 2/3 versus O-RADS 4/5 (kappa > 0.86). CA 125 improved performance of mUSR (P=0.002) and O-RADS (P=0.005) only in perimenopausal/postmenopausal patients.
CONCLUSION: O-RADS and mUSR both with high sensitivity and NPV for detection of ovarian malignancy but mUSR with significantly higher specificity and PPV than O-RADS. This finding endorses the American College of Radiology (ACR) recommendation for expert sonologist consultation for O-RADS 3 and 4.
引用
- Kajal D, Nanapragasam A, Leckie A, et al. Ultrasound Ovarian-Adnexal Reporting and Data System (O-RADS) and modified ultrasound simple rules comparison in evaluation of surgically proven adnexal masses. Clin Radiol. 2025. PMID: 41455177. doi:10.1016/j.crad.2025.107180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。